Posts tagged ‘pharma marketing’
This Friday sees the start of the 2011 annual meeting of the American Urological Association (AUA) in Washington, DC. The meeting runs from May 14-19.
We expect the recent FDA approval of abiraterone acetate (Zytiga®) from Ortho Biotech (JNJ) to be hot news at the meeting as urologists seek to learn more about it’s use.
Icarus Consultants will be in our Nation’s Capital for AUA, so should you be interested in meeting up, please contact us.
One element of brand positioning is ensuring that the messages about your product and how your customer sees it, are consistent. Messaging whether it be in the form of adverts, press releases or what key opinion leaders say is key to success in today’s information world.
Pieter Droppert on Biotech Strategy Blog, in his first video, outlines why he is attending Health Journalism 2011 in Philadelphia later this week. The annual meeting of the Association of Health Care Journalists offers the opportunity to see how the news makers approach topics.
You can see Pieter’s first video blog post below. Although video blogging takes longer to produce than writing a blog post, it is more engaging and we believe it is the way of the future. What do you think?
Icarus Consultants is a marketing strategy consulting company to biotechnology, pharmaceutical and life science companies. We don’t offer marketing communications services.
Source: Wikipedia
However, we like to keep our finger on the pulse of the market, so read with interest the recent United States Supreme Court decision in Matrixx Initiatives, Inc. v. Siracusano that involved a failure of Matrixx to share adverse event information with investors.
You may recall the issue of loss of smell associated with use of Zicam Cold Remedy Nasal Gel that contained zinc sulfate.
Matrixx argued that only statistically significant adverse events are material and need to be disclosed to investors, a position the Supreme Court disagreed with. In general terms, the Court held that adverse events that may be linked to a product that could impact a reasonable investor’s decision making need to be disclosed.
What’s the impact of this decision? The Matrixx decision will require companies and their PR agencies to think carefully about the need to include negative information as well as positive when making press releases. Clinical teams will need to talk to investor relations and marketing, something that may be a challenge in the silos of big pharma.
You can read more about this case, and a more in-depth analysis of Justice Sotomayor’s Supreme Court opinion on Biotech Strategy Blog.
Lupus or to use its full name, systemic lupus erythematosus (SLE) – try saying that after a few beers, is a nasty auto-immune disease. Sally Church on Pharma Strategy Blog discusses three recent research papers from Science Translational Medicine that provide new insight on the biology of this disease.
Sally asks, “can we improve treatment of lupus by understanding the biology better?”
Her review of the papers suggests that knowledge of the underlying biology of the disease may help develop new strategies for treating SLE. You can read Sally’s thoughtful post about the science and new products in development for Lupus on Pharma Strategy Blog.
“You are what you tweet”, sounds very philosophical but has an element of truth to it. Icarus Consultants’ social media guru, a.k.a. @MaverickNY on Pharma Strategy Blog
discusses a new app that turns your twitter stream into a word cloud.
What sentiments does your twitter stream says about you?
Sally Church on Pharma Strategy Blog continues her series of posts looking in more detail at Glioblastoma (GBM), the most common brain cancer.
Both brainstem gliomas and glioblastomas have poor prognosis, which raises the importance of translational medical research that could lead to new targeted therapies.
Research by Phillips et al, has shown that Akt and Notch signaling are hallmarks of poor prognosis, suggesting that identification of molecular subtypes may be useful in the development of new therapies.
Following on from the recent AACR special conference on targeting PI3K/mTOR signaling in cancer, Sally discusses in her blog post, the consequences that may follow from targeting the Akt pathway.
Michael J Fox Foundation announces positive results from Allon Therapeutics with davunetide in Parkinson's Disease
February 24th, 2011
Daedalus
The Michael J Foundation announced earlier this month positive preclinical data with davunetide in a mouse model of Parkinson’s Disease.
The drug is in clinical development by Vancouver based Allon Therapeutics for Alzheimer’s disease and other neurodegenerative disorders.
More about this interesting new product, its neuroprotective action and potential to slow down memory loss and cognitive decline can be found on Biotech Strategy Blog.
All those in the pharma/biotech industry who perform market research will be familiar with ESOMAR, the worldwide organization whose code of practice governs how we conduct market research.
So, we are pleased to be invited to the ESOMAR – Best of New York, 2011 event to be held at the offices of Microsoft in NYC, later today. Networking opportunities are always welcome, and Pieter Droppert from Icarus will be attending.
The meeting has four speakers covering a wide range of topics, including employing robots to mine twitter, and how to draw on the wisdom of crowds to generate winning concepts. It is good to have an opportunity to hear what other market research practitioners are doing outside of the pharma/biotech industry.
Information about the key opinion leader (KOL) market research services that Icarus Consultants offers can be found here.